Effectiveness of the use of non-hydrolysed type II collagen in the treatment of osteoarthritis: a systematic review and meta-analysis
DOI:
https://doi.org/10.34119/bjhrv6n1-131Keywords:
osteoarthritis, treatment, UC-IIAbstract
Objective: To evaluate the effectiveness of treating osteoarthritis with the use of type II non-denatured collagen (UCII). Methods: This is a study of systematic review and meta-analysis based on searches for randomized controlled clinical trials carried out in the PUBMED, SciELO, ScienceDirect and Google Scholar databases. 2009 and 2020 studies that analyzed the effectiveness of UCII in the treatment of patients with osteoarthritis using clinical and / or radiographic criteria and based on WOMAC and VAS scores were included. Results: A total of 4.850 references were found in the literature. When applying the inclusion criteria, there were only 4 studies suitable for selection, and 3 of them were possible to be included in the meta-analysis. All studies were carried out in patients with knee osteoarthritis and the total sample was 202 patients. Meta-analysis of WOMAC and VAS scores was performed in the three independent studies according to the intervention adopted, and heterogeneity was not significant in both (τ² = 0.0; I² = 0%). In the WOMAC and VAS scores, the point estimate for the difference in standardized means was -0.44 (95% CI=-0.72 to -0.16; 0.002) and -0.37 (95% CI = - 0.65 to -0.09; 0.010) respectively, thus, the intervention group had positive effects and favorable results compared to the control group. There was no publication bias for the WOMAC and VAS outcomes; Conclusion: Based on the results of this study, the use of the UCII is effective in the treatment of osteoarthritis to improve parameters of pain and mobility on WOMAC and VAS parameters.
References
Alfieri FM, Silva NC de OVE, Battistella LR. Study of the relation between body weight and functional limitations and pain in patients with knee osteoarthritis. Einstein (Sao Paulo). 2017;15(3):307–12.
Ferreira AH, Godoy PBG, Oliveira NRC de, Diniz RAS, Diniz REAS, Padovani R da C, et al. Investigação da ansiedade, depressão e qualidade de vida em pacientes portadores de osteoartrite no joelho: um estudo comparativo. Rev Bras Reumatol [Internet]. 2015;55(5):434–8. Available from: http://dx.doi.org/10.1016/j.rbr.2015.03.001
Prabhoo R, Billa G. Undenatured collagen type II for the treatment of osteoarthritis: a review. Int J Res Orthop. 2018;4(5):684.
Rezende MU of, Hernandez AJ, Camanho GL, Amatuzzi MM. Cartilagem Articular e Osteoartrose. Acta Ortopédica Bras. 2000;8(2):100–4.
Van Vijven JPJ, Luijsterburg PAJ, Verhagen AP, van Osch GJVM, Kloppenburg M, Bierma-Zeinstra SMA. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: A systematic review. Osteoarthr Cartil [Internet]. 2012;20(8):809–21. Available from: http://dx.doi.org/10.1016/j.joca.2012.04.008
Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: A clinical trial. Int J Med Sci. 2009;6(6):312–21.
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study. Nutr J [Internet]. 2016;15(1). Available from: http://dx.doi.org/10.1186/s12937-016-0130-8
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Humana y Diet. 2016;20(2):148–60.
Loures FB, Góes RF de A, Labronici PJ, Barretto JM, Olej B. Avaliação do índice de massa corporal como fator prognóstico na osteoartrose do joelho. Rev Bras Ortop [Internet]. 2016;51(4):400–4. Available from: http://dx.doi.org/10.1016/j.rbo.2015.08.007
Aguiar GC, Rocha SG, Rezende GA da S, Nascimento MR do, Scalzo PL. Effects of resistance training in individuals with knee osteoarthritis. Fisioter em Mov. 2016;29(3):589–96.
Bento T. Revisões sistemáticas em desporto e saúde: Orientações para o planeamento, elaboração, redação e avaliação. Motricidade. 2014;10(2):107–23.
Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Diz osteoartritli hastalarda nativ tip 2 kollajen tedavisinin değerlendirilmesi: Randomize kontrollü çalişma. Eurasian J Med. 2016;48(2):95–101.
Mehra A, Anand P, Borate M, Pal P, Kamble S, Dev Mehta K, et al. A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis. Int J Res Orthop. 2019;5(2):315.
Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res. 2003;311(3):393–9.
Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthr Cartil [Internet]. 2017;25(12):2080–90. Available from: https://doi.org/10.1016/j.joca.2017.08.013
Gupta RC, Canerdy TD, Skaggs P, Stocker A, Zyrkowski G, Burke R, et al. Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses. J Vet Pharmacol Ther. 2009;32(6):577–84.
Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: A mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3–4):101–10.
Marone PA, Lau FC, Gupta RC, Bagchi M, Bagchi D. Safety and toxicological evaluation of undenatured type II collagen. Toxicol Mech Methods. 2010;20(4):175–89.
